Pharmacovigilance Risk Assessment Committee (PRAC) recommends the revocation of the marketing authorizations of Esmya
9/4/2020
Business related Regulatory Marketing authorization application Women's Healthcare PRODUCT - ESMYA API - ULIPRISTAL ACETATE